Quantum BioPharma receives Buy rating as BOXABL expands modular housing

Quantum BioPharma (NASDAQ: QNTM) announced that Rodman & Renshaw has initiated coverage of the company with a Buy rating and an $8 price target. The research, led by biotechnology analyst Michael G. King Jr., focuses on the biopharmaceutical firm’s development of treatments for metabolic, neurodegenerative, and alcohol misuse disorders. Through its subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a compound designed to address myelin degradation in multiple sclerosis.

Separately, BOXABL Inc. (NASDAQ: BXBL) is expanding its factory-built housing platform following its recent listing on the Nasdaq. The company utilizes automation, AI, and advanced manufacturing to produce modular homes, including its initial Casita product. BOXABL aims to address the U.S. housing shortage and affordability crisis by providing modular solutions for single-family homes, multifamily developments, and commercial projects.